Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Background Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of tanibirumab in patients with solid tumors refractory to standard chemotherapy. Primary endpoints were evaluating safety, pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Su Jin, Lee, Seon Young, Lee, Weon Sup, Yoo, Jin San, Sun, Jong-Mu, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Ahn, Myung-Ju, Lim, Ho Yeong, Kang, Won Ki, Park, Young Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694508/
https://www.ncbi.nlm.nih.gov/pubmed/28391576
http://dx.doi.org/10.1007/s10637-017-0463-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694508/
https://www.ncbi.nlm.nih.gov/pubmed/28391576
http://dx.doi.org/10.1007/s10637-017-0463-y

Ejemplares similares